Cefpiramide Sodium

CHEMBL1200672 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
634.6 g/mol
LogP
Phase
4

The sodium salt formulation of cefpiramide is used intravenously for serious gram-negative infections where biliary excretion is advantageous. It shares the antibacterial spectrum and precautions of the parent compound including alcohol intolerance. It is not approved in North America or Western Europe but is used clinically in Asia.

Peso molecular

634,6000 g/mol

TPSA

262,00 Ų

Mecanismo de acción

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1.[Na+]

InChI

InChI=1S/C25H24N8O7S2.Na/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2;/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40);/q;+1/p-1/t17-,18-,23-;/m1./s1

Molecular Formula

C25H23N8NaO7S2

HBD / HBA

4 / 13

Enlaces Rotables

9

Átomos Pesados

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The sodium salt formulation of cefpiramide is used intravenously for serious gram-negative infections where biliary excretion is advantageous. It shares the antibacterial spectrum and precautions of the parent compound including alcohol intolerance. It is not approved in North America or Western Europe but is used clinically in Asia.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefpiramide Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200672. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23663969. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.